CTI BioPharma to Report Fourth Quarter and Full Year 2017 Financial Results on March 7, 2018

SEATTLE, Feb. 28, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management plans to report its fourth quarter and full year 2017 financial results on Wednesday, March 7, 2018, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a webcast conference call to discuss the results and provide a general corporate update at 4:30 p.m. ET (1:30 p.m. PT). Access to the event can be obtained as follows:

Wednesday, March 7, 2018
1:30 p.m. PT/4:30 p.m. ET/10:30 p.m. CET
1-800-289-0517 (domestic) 
+1 323-994-2084 (international)

To access the live audio webcast or the subsequent archived recording, visit CTI BioPharma's website, www.ctibiopharma.com. Webcast and telephone replays of the conference call will be available approximately two hours after completion of the call. Callers can access the replay by dialing 1-888-203-1112 (domestic) or +1 719-457-0820 (international). The access code for the replay is 2516357. The telephone replay will be available until Wednesday, March 14, 2018.

About CTI BioPharma

CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers. CTI BioPharma has a late-stage development pipeline, including pacritinib for the treatment of patients with myelofibrosis. CTI BioPharma is headquartered in Seattle, Washington. For additional information and to sign up for email alerts and get RSS feeds, please visit www.ctibiopharma.com.

CTI BioPharma Investor Contacts:
Tricia Truehart
+1 646 378 2953
ttruehart@troutgroup.com

View original content with multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-to-report-fourth-quarter-and-full-year-2017-financial-results-on-march-7-2018-300605650.html

SOURCE CTI BioPharma Corp.